US 10479839
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
granted A61KA61K2039/505A61K51/1072
Quick answer
US patent 10479839 (Internalizing human monoclonal antibodies targeting prostate cancer cells in situ) held by The Regents of the University of California expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K51/1072, A61P, A61P35/00